# Lumexa Imaging Holdings, Inc.: financial statements, quarterly

LMRI · Nasdaq · CIK 2071288 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lmri.md) · [Financials](/companies/lmri/financials.md) · [Filings](/companies/lmri/filings.md) · [Insiders](/companies/lmri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lmri/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [245](/filings/0001193125-26-219480.md) | [251](/filings/0001193125-26-348902.md) | [253](/filings/0001193125-26-219480.md) | [264](/filings/0001193125-26-348902.md) |
| Operating income | $m | [25.5](/filings/0001193125-26-219480.md) | [27.7](/filings/0001193125-26-348902.md) | [19.4](/filings/0001193125-26-219480.md) | [23.0](/filings/0001193125-26-348902.md) |
| Interest expense | $m | [29.8](/filings/0001193125-26-219480.md) | [30.1](/filings/0001193125-26-348902.md) | [16.3](/filings/0001193125-26-219480.md) | [16.2](/filings/0001193125-26-348902.md) |
| Income tax | $m | [3.4](/filings/0001193125-26-219480.md) | [4.8](/filings/0001193125-26-348902.md) | [1.4](/filings/0001193125-26-219480.md) | [3.0](/filings/0001193125-26-348902.md) |
| Net income | $m | [(7.7)](/filings/0001193125-26-348902.md) | [(7.2)](/filings/0001193125-26-348902.md) | [1.7](/filings/0001193125-26-348902.md) | [2.7](/filings/0001193125-26-348902.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001193125-26-219480.md) | [(0.10)](/filings/0001193125-26-348902.md) | [0.02](/filings/0001193125-26-219480.md) | [0.03](/filings/0001193125-26-348902.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0001193125-26-219480.md) | [(0.10)](/filings/0001193125-26-348902.md) | [0.02](/filings/0001193125-26-219480.md) | [0.03](/filings/0001193125-26-348902.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [58.8](/filings/0001193125-26-348902.md) | [51.2](/filings/0001193125-26-219480.md) | [69.7](/filings/0001193125-26-348902.md) |
| Current assets | $m | not reported | not reported | not reported | [227](/filings/0001193125-26-348902.md) | [222](/filings/0001193125-26-219480.md) | [256](/filings/0001193125-26-348902.md) |
| Total assets | $m | not reported | not reported | not reported | [1,765](/filings/0001193125-26-348902.md) | [1,763](/filings/0001193125-26-219480.md) | [1,809](/filings/0001193125-26-348902.md) |
| Current liabilities | $m | not reported | not reported | not reported | [179](/filings/0001193125-26-348902.md) | [158](/filings/0001193125-26-219480.md) | [178](/filings/0001193125-26-348902.md) |
| Total liabilities | $m | not reported | not reported | not reported | [1,178](/filings/0001193125-26-348902.md) | [1,164](/filings/0001193125-26-219480.md) | [1,194](/filings/0001193125-26-348902.md) |
| Long-term debt | $m | not reported | not reported | not reported | [819](/filings/0001193125-26-348902.md) | [817](/filings/0001193125-26-219480.md) | [820](/filings/0001193125-26-348902.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [13.1](/filings/0001193125-26-348902.md) | [13.4](/filings/0001193125-26-219480.md) | [14.3](/filings/0001193125-26-348902.md) |
| Shareholders' equity | $m | [162](/filings/0001193125-26-348902.md) | [161](/filings/0001193125-26-348902.md) | [162](/filings/0001193125-26-348902.md) | [586](/filings/0001193125-26-348902.md) | [600](/filings/0001193125-26-348902.md) | [615](/filings/0001193125-26-348902.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.0)](/filings/0001193125-26-219480.md) | [2.1 d](/filings/0001193125-26-348902.md) | [2.9](/filings/0001193125-26-219480.md) | [32.8 d](/filings/0001193125-26-348902.md) |
| Capital expenditure | $m | [1.0](/filings/0001193125-26-219480.md) | [4.6 d](/filings/0001193125-26-348902.md) | [5.3](/filings/0001193125-26-219480.md) | [9.7 d](/filings/0001193125-26-348902.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [69.5](/filings/0001193125-26-219480.md) | [69.5](/filings/0001193125-26-348902.md) | [96.0](/filings/0001193125-26-219480.md) | [96.0](/filings/0001193125-26-348902.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,074,976 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-348902.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.